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Renal flares in 91 SLE patients with diffuse proliferative glo- [1–3]. Despite continual improvements in therapy, an
merulonephritis. average of 25% of patients with lupus nephritis evolve
Background. Even when treated with current protocols, 25 to end-stage renal disease (ESRD) [4–9]. Among theto 30% of systemic lupus erythematosus (SLE) patients with
many prognostic factors for a poor renal outcome re-diffuse proliferative glomerulonephritis (DPGN) evolve to
ported in various studies, the occurrence of nephriticend-stage renal disease (ESRD). The occurrence of renal flares
is considered to be an important risk factor for the evolution flares during the follow-up appears to be significant
to ESRD. The aim of this retrospective study was to evaluate [10, 11]. For this reason some authors have suggested
the incidence and prognostic significance of renal flares in SLE prolonging immunosuppressive treatment in order to re-patients with DPGN and to identify predictors for the occur-
duce the incidence of flares in SLE patients with DPGNrence of flares.
[9]; such an approach, however, carries a high risk ofMethods. Ninety-one SLE patients were selected for study
based on the following criteria: (a) evidence of renal involve- side effects such as the development of cancer and amen-
ment, (b) a follow-up of at least 6 months after the renal biopsy, orrhea [12, 13].
and (c) a steady improvement in renal manifestations after the Since the identification of a subgroup of patients atbiopsy lasting for at least three months.
high risk of flares would allow for a more precise tailoringResults. Renal flares occurred in 54% of the patients after
of the therapeutic approach to lupus nephritis, in thisrenal biopsy and appropriate treatment. A younger age at the
time of renal biopsy correlated with the occurrence of renal retrospective study we evaluated the incidence of renal
flares. A high activity index (10) and karyorrhexis on histol- flares and looked for predictors of the occurrence of
ogy correlated with the occurrence of nephritic flares. Twenty-
such flares in a large series of SLE patients with DPGNseven percent of the patients developed ESRD. The number
who were followed at our Unit.of renal flares, nephritic flares, and “early” proteinuric flares
(that is, those occurring in the first 18 months after renal biopsy)
as well as serum creatinine levels, karyorrhexis, and chronicity
METHODSindex on renal histology were correlated with doubling serum
creatinine. Patients
Conclusions. Our results suggest that (a) a distinct subgroup
From a pool of 98 SLE patients with biopsy-provenof SLE patients exists, made up of younger patients with exten-
sive, active lesions on renal biopsy, who are at higher risk for DPGN who underwent treatment and follow-up at the
renal flares, (b) renal flares represent important predictors of Rheumatology Unit of the University of Pisa during the
doubling serum creatinine. period between 1976 and 2000, 91 were selected for this
study based on the following criteria: (a) clinical and
histological evidence of renal involvement, (b) a follow-
The occurrence of nephritis, particularly diffuse prolif- up of at least six months after the renal biopsy, and (c)
erative glomerulonephritis (DPGN), remains one of the an improvement in renal manifestations over a period
most important factors influencing the long-term prog- of at least three months after the biopsy [8, 14].
nosis of systemic lupus erythematosus (SLE) patients In all 91 patients, treatment had been instituted imme-
diately after the biopsy. The incidence of a renal flare
or flares during follow-up was chosen as primary endKey words: systemic lupus erythematosus, diffuse proliferative glomer-
ulonephritis, renal flares, renal outcome, end-stage renal disease. point of this study; as a secondary end point, the renal
outcome at the end of follow-up also was considered.Received for publication May 14, 2001
Patients who did not respond to the therapy were ex-and in revised form November 7, 2001
Accepted for publication November 19, 2001 cluded. Remission was defined as a steady improvement
in serum creatinine, increase in complement levels, nor- 2002 by the International Society of Nephrology
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malization of urine sediment and 24-hour proteinuria activity index (AI) and chronicity index (CI) according
to the criteria proposed by Austin et al [17, 18]. The1 g/day over a period of at least three months following
the initiation of treatment. Partial remission was defined predictive value of these histological variables for the renal
outcome was then analyzed. The AI and CI values alsoas a steady improvement in serum creatinine, 50%
decrease in hematuria, significant change in proteinuria were converted to dichotomous variables, using different
cut-off values as previously described [10, 18, 20–22].over a period of at least three months following the
initiation of treatment [15]. Patients who responded to
Statistical analysistherapy were monitored for the appearance of flares.
Renal flares were defined using the criteria of Moroni The Mann-Whitney U-test was used to correlate the
outcomes with the clinical, serological and histologicalet al as follows: (a) nephritic flares, defined as an increase
in plasma creatinine of at least 30% over the basal value, variables. For categorical variables the 2 test was used.
A logistic regression model as a predictor of renal flaresnephritic urinary sediment, increased proteinuria; and
(b) proteinuric flares, defined as an increase in protein- or renal outcome was applied to epidemiological, clini-
cal, serological and histological variables that potentiallyuria by at least 2 g/day or doubling if basal proteinuria
is above 3.5 g/day, without modification of plasma creati- could influence the occurrence of these events. Partic-
ularly, the following data were analyzed: the role of ini-nine [10].
A poor renal outcome was defined as a doubling in tial creatinine values, age at the time of renal biopsy,
ECLAM values at biopsy, AI 10 on the occurrence ofserum creatinine values for a period of at least six months,
with a plasma creatinine value of at least 2 mg/dL [15]. flares [abstract; Takada K et al, Lupus (Suppl 1):S16;
2001] [10, 11, 22], and the role of serum creatinine valuesData were recorded at the moment of the renal biopsy,
at the occurrence of each renal flare and at the end at biopsy, age at the time of renal biopsy, ECLAM values
at biopsy, CI considered as a continuous variable, andof the follow-up period. The values for the following
parameters were obtained from the clinical charts and an AI 10 on the occurrence of a poor renal outcome
correlated with the outcome: age, SLE duration, dura- [10, 11, 17–21].
tion of renal involvement before the biopsy, disease ac- Survival analysis was used to evaluate the relationship
tivity as measured by ECLAM [16], hypertension, serum between epidemiological and histological lesions and re-
creatinine levels, complement levels, 24-hour protein- nal flares or renal outcome. For this purpose, the pa-
uria, and urinary sediment. tient’s age at the time of the renal biopsy and the AI
Hypertension was considered to be present when the and CI on his/her renal biopsy were dichotomized [10,
diastolic pressure was persistently above 90 mm Hg and 18, 20–22]. The survival time was defined as the interval
antihypertensive therapy had been instituted [17]. Hypo- from the moment of the biopsy to the study end-point
complementemia was defined as a decrease in serum C3 (renal flare or the end of the follow-up). Survival curves
and C4 levels below the lower limit of normal for testing (Kaplan-Meier) were compared by the log rank test. In
laboratory [16]. Nephrotic range proteinuria was defined view of the large number of correlations determined, a
as values 3.5 g/day [10]. significance level of 1% was adopted; a significance level
Data on the treatment received by the patients also with a probability 5% but 1% is quoted only when
were collected from the clinical charts. Since this was a it provides confirmation of an association already de-
retrospective study covering a 24-year period (1976 to scribed in the literature.
2000), there were inevitably significant differences in the
induction therapies used. To overcome this problem we
RESULTSfocused in our data analysis on the administration of
Using the criteria described above, 91 patients (8 malesimmunosuppressive drugs and identified two main thera-
and 83 females) were selected for study from a pool ofpeutic protocols: (a) high-dose steroids alone (IV or
98 SLE patients with DPGN who had been treated andpulse), or (b) steroids associated with immunosuppres-
followed up at our Unit during the period between 1976sive drugs, usually cyclophosphamide (CPM). Cyclo-
and 2000. The remaining seven were excluded for thephosphamide was given as pulse therapy, either 500 mg
following reasons: four were lost to follow-up after theweekly or 1000 mg monthly, up to a maximum of 9
renal biopsy, one died of pulmonary embolism twopulses. No maintenance treatment with azathioprine or
months after the renal biopsy, and two did not respondother immunosuppressive drugs was given after CPM
to treatment. These two patients developed end-stagetherapy. Renal flares were treated with pulse steroids
renal disease and had to be placed on dialysis.alone or in association with pulse cyclophosphamide,
Table 1 summarizes the epidemiological, clinical andeither 500 mg weekly or 1000 mg monthly, up to a maxi-
serological features of the 91 patients. Four patients diedmum of 9 pulses.
after a follow-up of 28 to 84 months, and in view of theRenal biopsy samples from 79 of the patients were
still available and were analyzed to obtain the patient’s length of their follow up these patients were included in
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Table 1. Principal epidemiological, clinical and histological features
in the 91 systemic lupus erythematosus (SLE) patients with diffuse
proliferative glomerulonephritis (DPGN) included in the study
Parameter
M:F 8:83
Duration of SLE months 49 (range 49–74, median 24)
Duration of renal disease before
biopsy 25 days (range 10–60; median 20)
Duration of follow-up from renal
biopsy to renal outcome/last
observation months 82 (range 12–288; median 72)
Total follow-up after biopsy
months 93 (range 12–288; median 80)
Age years 31 (range 14–64; median 30)
ECLAM 6 (range 1–10; median 7)
Activity index 8 (range 1–24; median 7)
Chronicity index 1 (range 0–12; median 0)
Plasma creatinine at presentation 1.1 (range 0.6–5, median 0.85)
Patients with abnormal serum
creatinine 23%
Proteinuria g/24 h 3.7 (range 0.5–14; median 2.7)
Fig. 1. Risk of renal flare according to age. Survival analysis (absencePatients with nephrotic syndrome 64%
of renal flares) of the period between the initiation of therapy and thePatients with hypocomplementemia 100%
time of occurrence of the first flare demonstrated the prognostic valuePatients with hypertension 41%
of age at the time of biopsy [(dashed line) 30 years vs. (solid line)
30 years]; a younger age was associated with an increased risk (P 
0.01, log rank test). At 5 years the probability of not flaring was 65%
(21 patients at risk of flaring) versus 26% (12 patients at risk of flaring)
for patients with age30 versus age30 years, respectively; at 10 years
our analysis and treated as observations censored at the the probability of not flaring was of 58% versus 23% in the two groups.
time of death. Two patients presented a renal flare during
the follow up, while two did not. The reasons for death
were: cardiovascular disease, viral encephalitis, bowel these 49 patients who presented renal flares, 28 (57%)
perforation after colonscopy; in one patient the cause of showed a good renal outcome, 9 (18%) a doubling of
death was unknown. serum creatinine, and 12 (25%) were on dialysis.
Forty patients were treated with steroids alone: 22 Survival analysis of the period between the initiation
patients with oral steroids and 18 with pulse therapy. of therapy and the time of occurrence of the first flare
Fifty-one patients (56%) were treated with immunosup- demonstrated the prognostic value of age at the time of
pressive drugs (46 pulse cyclophosphamide, 4 azathio- biopsy (30 years vs. 30 years); a younger age was
prine, 1 cyclosporin A) after DPGN was diagnosed. associated with an increased risk (P  0.01; Fig. 1). The
activity index (AI) showed a similar prognostic valueRenal flares
(P  0.005; Fig. 2), and an AI10 was associated with a
Forty-nine patients (54%) experienced a renal flare; higher risk of flares. Closer inspection, however, showed
the mean time lapse between the renal biopsy and the that the predictive value of AI was limited to the occur-
flare was 42 months (range 6 to 228 months; median 30 rence of nephritic flares (P  0.001 vs. P  NS for
months) and the overall follow-up period in the patients proteinuric flares). As suggested by Magil et al, the pres-
not presenting renal flares was 68 months (P  NS); the ence of karyorrhexis was the parameter (among those
mean follow-up of patients presenting a renal flares was making up the AI) that contributed most to the predic-
95 months (P  NS). Twenty-eight flares (57%) were tion of nephritic flares (P 0.05) [20]. These results also
proteinuric in nature, and 21 (43%) were nephritic. Most were confirmed by logistic regression.
of the nephritic flares occurred within 62 months after Induction therapy (steroids alone vs. steroids plus im-
the renal biopsy (mean 26 months), while the proteinuric munosuppressive drugs) did not seem to alter the timing
flares tended to occur later, a mean of 54 months after of the flares (P  NS; Fig. 3), although the curve does
the renal biopsy. Twenty-three patients experienced suggest a reduced long-term risk in patients treated with
more than one flare: two flares each in 16 patients, three immunosuppressive drugs. It should be noted, however,
flares each in four patients, and five flares each in three that the follow-up period for the patients given immuno-
patients. A cumulative number of 85 flares was observed; suppressive therapy was shorter than for those who re-
39 (46%) were proteinuric flares and 46 (54%) were ceived steroids alone.
nephritic. Fifty-five flares (65%) were treated with pulse
Renal outcomesteroids and pulse cyclophosphamide; 30 flares (35%)
were treated with high dose steroids (17 as pulse therapy Twenty-five patients (27%) exhibited a poor renal out-
come after a mean follow-up time of 63 months post-and 13 as oral steroids). At the end of the follow-up, of
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Fig. 2. Risk of renal flares according to the activity index (AI). Survival Fig. 4. Risk of poor renal outcome of 91 systemic lupus erythematosus
(SLE) patients. At 5 years the probability of doubling serum creatinineanalysis (absence of renal flares) based on AI values 10 (dotted line)
or 10 (solid line) demonstrated the prognostic significance of AI, as is 21% (50 patients at risk); at 10 years the probability of doubling of
serum creatinine is 38% (21 patients at risk).an AI 10 was associated with a higher risk of flares (P  0.005, log
rank test). At 5 years the probability of not flaring was of 53% (22
patients at risk of flaring) versus 27% (6 patients at risk for flaring) for
patients with low and high AI, respectively. At 10 years the probability
of not flaring was of 50% versus 21%, respectively.
Table 2. Clinical status of the patients at their last observation
Parameter
Patients in complete remission 55 (60%)
Patients in partial remission 11 (12%)
Patients with poor outcomea 25 (28%)
Patients in dialysis 13 (14%)
Plasma creatinine at last observationb 1.2 (range 0.6–5; median 0.9)
Proteinuria g/24 hb 0.6 (range 0–2.5; median 0.4)
Patients with hypertensionb 30 (38%)
a Defined as a doubling in serum creatinine values for a period of at least 6
months, with a plasma creatinine value of at least 2 mg/dL [15]
b Excluding patients in dialysis
biopsy (P 0.01), the composite CI as well as its separate
components (P 0.001) on renal histology. The presence
of karyorrhexis, which was reported to correlate with a
poor renal outcome [19–20], did not reach our predefined
level of significance, its P value being 0.025.
Survival analysis of the period between the renal
biopsy and the time of doubling serum creatinine (renal
end point) demonstrated the prognostic value of in-
creased serum creatinine and increased CI (3 vs. 3;
Fig. 3. Risk of renal flares according to the initial treatment with (heavy Figs. 5 and 6). The occurrence of nephritic flares (P 
solid line) steroids alone versus (thin solid line) steroids plus immuno- 0.001; odds ratio 9.16, 95% CI 2.48  33.9) and numbersuppressive drugs. In the survival analysis (absence of renal flares), the
of renal flares (both proteinuric and nephritic; P therapy did not seem to alter the timing of the flares (PNS), although
the curve suggests that there is a reduced long-term risk in patients 0.001), also were significantly correlated with a poor re-
treated with immunosuppressive drugs. nal outcome. The occurrence of proteinuric flares as such
was not predictive of a poor renal outcome; however,
when analyzed based on their time of occurrence, a poor
outcome was correlated with flares that took place inrenal biopsy (range 13 to 144 months; median 58; Fig.
4), and among these, 13 became dialysis-dependent (Ta- the first 18 months after renal biopsy (“early” proteinuric
flares; P  0.01 vs. no flare and late proteinuric flares;ble 2). Among the epidemiological, clinical, laboratory
and histological variables examined, the following were odds ratio 9.3, 95% CI 1.8447.2). These results were
confirmed by logistic regression.found to be significantly associated with a poor renal
outcome: serum creatinine levels at the time of renal To further understand the prognostic value of renal
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Fig. 5. Risk of doubling serum creatinine based on serum creatinine
Fig. 7. Survival analysis (poor renal outcome) for patients with a fol-values at the time of renal biopsy, for serum creatinine 1.2 (dotted
low-up of at least 5 years who had (dashed line) or did not have (solidline, abnormal creatinine) or 1.2 (solid line; normal creatinine). The
line) renal flares in the first 5 years after renal biopsy. The occurrencesurvival time is defined as the interval from the moment of the biopsy
of renal flares was correlated with a poor renal outcome (P  0.01; logto the doubling of serum creatinine (P  0.01; log rank test). Survival
rank test). At 10 years after the renal biopsy, the probability of notanalysis (poor renal outcome) demonstrated that at 5 years the probabil-
doubling serum creatinine was 50% (7 patients at risk of poor outcome)ity of not doubling serum creatinine was 73% (13 patients at risk of
versus 84% (14 patients at risk of poor outcome) in patients who hadpoor renal outcome) versus 81% (37 patients at risk of poor renal
renal flares versus patients who did not have renal flares. At 15 yearsoutcome) for patients with elevated versus normal serum creatinine.
the probability of not doubling serum creatinine was 33% versus 84%,At 10 years the probability of not doubling serum creatinine was 36%
respectively.versus 72%, respectively.
patients were then divided in two groups according to
their having flared (31 patients) or not (28 patients) in
the first five years of their disease. The resulting probabil-
ity of a poor renal outcome was found to be higher for
patients who had a renal flare (P  0.01; Fig. 7).
DISCUSSION
In the present study the occurrence of renal flares and
the renal outcome in a population of 91 patients with
biopsy-proven DPGN were examined. Forty-nine pa-
tients (54%) experienced at least one renal flare after
treatment, and analysis of their data showed that: (i) a
younger age at the time of renal biopsy was significantly
Fig. 6. Risk of doubling serum creatinine according to chronicity index correlated with the occurrence of renal flares; and (ii) a
on renal biopsy. Survival analysis for patients with chronicity index high activity index (AI10) and the presence of karyor-(CI) 3 (dotted line) or 3 (solid line) demonstrated the prognostic
rhexis on renal histology were correlated with nephriticrole of CI. A CI above 3 was correlated with doubling of serum creati-
nine (P 0.001; log rank test). At 5 years the probability of not doubling flares. Twenty-five patients (27%) had a poor renal out-
serum creatinine was 38% (4 patients at risk of poor renal outcome)
come, and analysis of their data showed a correlationversus 83% (37 patients at risk of poor renal outcome) for patients
with high and low CI, respectively. At 10 years the probability of not with the following parameters: the number of renal flares
doubling serum creatinine was 14% versus 69%, respectively. (both proteinuric and nephritic); the occurrence of ne-
phritic flares or “early” (within 18 months after the renal
biopsy) proteinuric flares; high serum creatinine levels
at the time of renal biopsy; the presence of karyorrhexis;flares on the time course of the disease, the analysis also
and a raised CI (including all of its components) on renalwas limited to those patients with a total observation
histology.time of at least five years. Indeed, patients with a shorter
Concerning renal flares, our results are only in partialobservation time may not have the time to develop flares
agreement with previously published data because the(or doubling of serum creatinine), since the risk of flaring
cumulative incidence of flares in our patient populationremains for the entire period of follow-up (albeit it is
higher in the first years of disease). The resulting 59 was high compared with some other studies [9–11, 22–
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Table 3. Data in the literature on renal flares and renal outcome in SLE patients with DPGN
Flares Poor outcome
No. of Follow-up
Author (year) [Reference] patients months %
Boumpas et al (1992) [8] 40 60 22.5 25
Sesso et al (1994) [23] 27 14.4 14 28
Pablos et al (1994) [24] 11 48 36 not evaluated
Ciruelo et al (1996) [22] 48 33 25–46 not evaluated
Gourley et al (1996) [9] 17 12 7 20
Moroni et al (1996) [10] 70 127 66 20
Ioannidis et al (2000) [25] 85 31 50 not evaluated
Mosca et al (2000) [27] 34 51 45 27
Mosca et al (2001) 91 93 54 25
25]. Since for the biopsy evaluations the same endpoints, an AI10 and the presence of karyorrhexis were associ-
ated with an increased risk of renal flares. This confirmsdefinitions and scoring systems were used as those
adopted by other authors, these data can be excluded the results obtained by us in a recent analysis of 33 SLE
patients with DPGN who were treated with pulse CPM,as possible causes of the discrepancy; other factors must
be examined to explain the difference. in which a younger age and high AI were found to be
correlated with the higher incidence of renal flares [26].For example, differences in the length of the follow-up
period after renal biopsy might account for the differing Discrepancies in some of the other results obtained be-
tween that study and the present one may be attributedincidence of renal flares. The incidence of flares reported
in three studies with a long follow-up period were quite to the fact that in the former study all 33 patients were
treated with immunosuppressive drugs. The similar find-similar to ours: 46% in the study by Ciruelo et al [22],
50% in the one by Ioannidis et al [25], and 44% in a ings for age and AI obtained suggest that these factors
may be related to the “natural history” of the diseasepreliminary study by Takada et al [abstract; Lupus
(Suppl 1):S16, 2001]. and therefore may be independent of the therapeutic
protocol used.Another confounding factor could be the role of ther-
apy, since some of our patients did not receive immuno- Our finding that age may be a prognostic factor for
renal flares is in agreement with other reported data, insuppressive drugs, and treatment with steroids alone has
been associated with an increased incidence of renal particular with the observation that younger patients
with lupus nephritis often have a more aggressive diseaseflares [9]. Although this represents a possible bias in our
study, it should be observed that the incidence of flares course [18, 27]. The prognostic significance of karyorr-
hexis found in our study is consistent with descriptionsalso is high in patients treated with immunosuppressive
drugs, as we have shown in a previous analysis of 33 of karyorrhexis as a severe and fulminant lesion [19, 20].
On the other hand, in contrast to previous studies [10,patients and as shown by Takada et al [abstract; Lupus
(Suppl 1):S16; 2001]. This observation may support the 11, 22–25] we did not find the patient’s sex or any other
serological or clinical variables (including serum creati-hypothesis that flares may represent an important aspect
of the natural history of lupus nephritis in spite of the nine levels, hypertension, proteinuria, disease activity,
or chronic lesions) to be correlated with the occurrencetherapeutic protocol adopted.
Other authors have already studied the risk factors of flares. These discrepancies may be attributable to the
patient selection criteria used, but also could reflect thefor the occurrence of renal flares. In 1996 Moroni et
al found that male sex and arterial hypertension were fact that, as suggested by Austin and Balow [28], the treat-
ment itself could modify the inherent impact of some ofassociated with the risk of developing nephritic renal
flares [10]. In 1996 Ciruelo reported that a younger age the prognostic features of lupus nephritis. The finding
that chronic lesions are not predictive of flares confirms(29 years) at the diagnosis of nephritis, a delay of more
than five months from the diagnosis to CFX therapy, and their significance as a damage index rather than an activ-
ity index.a chronicity index 3 on renal biopsy were significantly
associated with the risk of renal flares [22]. Most recently, Concerning outcome, in agreement with previously
published data the incidence of a poor renal outcomein 2000 Ioannidis showed a significant correlation be-
tween the occurrence of renal flares and CNS disease at in our series was 27% (Table 3). Among the variables
examined serum creatinine levels, karyorrhexis, thenephritis onset, DPGN and the time to remission [25].
Other predictive factors for the occurrence of renal flares chronicity index and its components on renal histology,
the number of renal flares (both proteinuric and ne-are an AI 7 and treatment with steroids alone [11].
In our study a younger age at the time of renal biopsy, phritic), the occurrence of nephritic flares, and the occur-
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in systemic lupus erythematosus during a 5-year period: A multi-rence of “early” proteinuric flares (that is, within the
center prospective study of 1000 patients followed from 1990 to
first 18 months after renal biopsy) were all correlated 1995. Medicine (Baltimore) 78:167–175, 1999
3. Bono L, Cameron JS, Hicks JA: The very long-term prognosiswith a poor renal outcome.
and complications of lupus nephritis and its treatment. Quart J MedFew data are available on the prognostic significance
92:211–218, 1999
of renal flares in patients with lupus nephritis. Moroni et 4. Austin HA, Balow JE: Natural history and treatment of lupus
nephritis. Semin Nephrol 19:2–11, 1999al found that nephritic flares were significantly associated
5. Bansal VK, Beto JA: Treatment of lupus nephritis: A meta-with a poor renal outcome [10]. Our study confirms this
analysis of clinical trials. Am J Kidney Dis 29:193–199, 1997
finding, but also detected a correlation between outcome 6. Austin HA 3rd, Klippel JH, Balow JE, et al: Therapy of lupus
nephritis. Controlled trial of prednisone and cytotoxic drugs.and early proteinuric flares. The occurrence of such early
N Engl J Med 314:614–619, 1986flares in a patient who is apparently in clinical and sero-
7. Steinberg AD, Steinberg SC: Long-term preservation of renal
logical remission could indicate that the disease has not function in patients with lupus nephritis receiving treatment that
includes cyclophosphamide versus those treated with prednisoneyet been brought under control.
only. Arthritis Rheum 34:945–950, 1991The value of other factors in predicting renal outcome
8. Boumpas DT, Austin HA III, Vaughn EM, et al: Controlled
has already been thoroughly studied. Most studies that trial of pulse methylprednisolone versus two regimens of pulse cyclo-
phosphamide in severe lupus nephritis. Lancet 340:741–745, 1992have examined the prognostic role of histological lesions
9. Gourley MF, Austin HA, Scott D, et al: Methylprednisolonein DPGN agree that the presence of very severe active
and cyclophosphamide, alone or in combination, in patients with
lesions such as karyorrhexis or chronic lesions represents lupus nephritis. A randomized, controlled trial. Ann Intern Med
125:549–557, 1996a predictive factor for a poor outcome [19–21, 27, 29–31].
10. Moroni G, Quaglini S, Maccario M, et al: “Nephritic flares”In conclusion, this study shows that: (a) a younger age
are predictors of bad long-term renal outcome in lupus nephritis.
at the time of renal biopsy represents a risk factor for Kidney Int 50:2047–2053, 1996
11. Ponticelli C, Moroni G: Flares in lupus nephritis: Incidence,flares; (b) an activity index 10 and the presence of
impact on renal survival and management. Lupus 7:635–638, 1998karyorrhexis constitute risk factors for nephritic flares;
12. Boumpas DT, Austin HA, 3rd, Vaughan EM, et al: Risk for sus-
and (c) nephritic renal flares and early proteinuric flares tained amenorrhea in patients with systemic lupus erythematosus
receiving intermittent pulse cyclophosphamide therapy. Ann Internare predictive of a poor renal outcome. These observa-
Med 119:366–369, 1993tions suggest that younger patients with karyorrhexis and
13. Kinlen LJ: Incidence of cancer in rheumatoid arthritis and other
an AI 10 should be considered as candidates for more disorders after immunosuppressive treatment. Am J Med 78(Suppl
1A):44–49, 1985aggressive and prolonged treatment.
14. D’Cruz D, Cuadrado MJ, Mujic F, et al: ImmunosuppressiveWe are aware of the limits of a retrospective study.
therapy in lupus nephritis. Clin Exp Rheumatol 15:275–282, 1997
In the series of patients studied here different treatment 15. Boumpas DT, Balow JE: Outcome criteria for lupus nephritis
trials: A critical overview. Lupus 7:622–629, 1998protocols were used and it is difficult to evaluate the
16. Vitali C, Bencivelli W, Isemberg DA, et al: Disease activityrelative impact this might have had on the results. Never-
in systemic lupus erythematosus: Report of the Consensus Study
theless, we are convinced that the results obtained pro- Group of the European Workshop for Rheumatology Research.
vide useful indications that could be further explored in II. Identification of the variables indicative of disease activity and
their use in the development of an activity score. Clin Exp Rheuma-a prospective study on the significance of flares in lupus
tol 10:541–547, 1992nephritis. In particular, the factors identified in this study 17. Mosca M, Pasquariello A, Tavoni A, et al: Predictors of renal
could be used to find those patients at risk of flares or outcome in diffuse proliferative glomerulonephritis in systemic
lupus erythematosus. Lupus 6:371–378, 1997a poor outcome, so that the duration of their immunosup-
18. Austin HA, Muenz LR, Joyce KM, et al: Prognostic factors inpressive therapy can be adjusted accordingly. Future pro- lupus nephritis. Contribution of renal histologic data. Am J Med
spective studies are needed to confirm our observations, 75:382–391, 1983
19. Austin HA, Muenz LR, Joyce KM, et al: Diffuse proliferativeand to study the influence of immunosuppressive treat-
lupus nephritis: Identification of specific pathologic features affect-ments on the natural history of lupus nephritis. ing renal outcome. Kidney Int 25:689–695, 1984
20. Magil AB, Puterman ML, Ballon HS, et al: Prognostic factors
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